This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioTime Forms New Subsidiary, OrthoCyte Corporation, To Develop Treatments For Orthopedic Conditions Using Stem Cell Technology

BioTime, Inc. (NYSE Amex: BTIM) announced today that it has organized a new subsidiary, OrthoCyte Corporation, for the purpose of developing novel therapeutics based on stem cell technology for the treatment of injuries and disorders affecting the musculoskeletal system, including therapeutics that would regenerate bone, cartilage, tendons and ligaments. BioTime will transfer certain patents and license certain technology to OrthoCyte for use in the field of orthopedic therapies.

Arnold I. Caplan, Ph.D., Professor of Biology and General Medical Sciences and director of the Skeletal Research Center at Case Western Reserve University, will be OrthoCyte’s Chief Scientific Officer as a part-time employee while maintaining his faculty position. Dr. Caplan is an internationally renowned scholar in the field of musculoskeletal and skin development research. Dr. Caplan has authored more than 350 published papers and manuscripts relating to the development, maturation and aging of cartilage, bone, skin, other connective tissues, and mesenchymal stem cells. Dr. Caplan previously founded Osiris Therapeutics, Inc., a public company focused on adult mesenchymal stem cell technology.

“I am hugely interested in working to further advance the sophistication of the field of regenerative medicine where it is now possible to parse with greater purity the diverse embryonic progenitors to the musculo-skeletal system,” said Dr. Caplan. “The isolation of precise embryonic progenitors to clinically-important tissues finally opens the door to the development of a wide array of powerful new cell-based therapies and tissue engineering for degenerative diseases such as osteoarthritis. I look forward to working with BioTime to speed these potential therapeutics toward clinical use.”

“A wide array of novel and potentially valuable therapies have been made possible by the development of human embryonic stem cell technology,” said Michael West, Ph.D., BioTime’s CEO. “The formation of OrthoCyte is another step in BioTime’s long-term strategy to create value for our shareholders by forming subsidiaries focused on specific therapeutic applications of our technology. We previously organized OncoCyte Corporation to develop products for the treatment of cancer, and Embryome Sciences, Inc., to develop and market products for stem cell research purposes. Similarly, our formation of BioTime Asia, Limited, and our acquisition of ES Cell International Pte Ltd offer the possibility of accelerating the commercialization of diverse therapeutic and research applications of stem cells in the People’s Republic of China and other countries in Asia. Dr. Caplan is a true luminary in stem cell-based therapies for orthopedic disorders. With his involvement, we plan to institute an aggressive collaborative program of product development.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs